Partial
Mostly Aligned
Patient Risk:
Low
Summary
Two medication-use claims are supported by the provided label text (indications for nonvalvular atrial fibrillation, DVT, and PE). However, the remaining claims concern patents/generic/biosimilar timing and unrelated industry statements, which are not supported or contradicted by the provided prescribing information excerpts.
Category Scores
Accurate Statements
Xarelto (rivaroxaban) is an anticoagulant used to prevent stroke and blood clots in patients with non-valvular atrial fibrillation.
Supported for the indicated use: “XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.” (Label section 1.1).
Xarelto (rivaroxaban) is used to treat deep vein thrombosis.
Supported: “XARELTO is indicated for the treatment of deep vein thrombosis (DVT).” (Label section 1.2).
Xarelto (rivaroxaban) is used to treat pulmonary embolism.
Supported: “XARELTO is indicated for the treatment of pulmonary embolism (PE).” (Label section 1.3).
Unsupported Statements
As of 2022, Xarelto is under patent protection held by Janssen Pharmaceuticals.
Not addressed in the provided prescribing information excerpts.
The patent for Xarelto in the US is expected to expire on May 5, 2029.
Not addressed in the provided prescribing information excerpts.
Mylan (now part of Upjohn) has announced plans to launch a generic version of Xarelto.
Not addressed in the provided prescribing information excerpts.
Teva Pharmaceuticals has announced plans to launch a generic version of Xarelto.
Not addressed in the provided prescribing information excerpts.
Dr. Reddy's Laboratories has announced plans to launch a generic version of Xarelto.
Not addressed in the provided prescribing information excerpts.
Sandoz Pharmaceuticals (now part of Novartis) has announced plans to launch a generic version of Xarelto.
Not addressed in the provided prescribing information excerpts.
Hetero Drugs has announced plans to launch a generic version of Xarelto.
Not addressed in the provided prescribing information excerpts.
The approval process for biosimilars can take several years.
Not addressed in the provided prescribing information excerpts.
Companies must provide extensive data demonstrating the equivalence of their biosimilar to the originator product.
Not addressed in the provided prescribing information excerpts.
There are ongoing discussions and debates within the industry regarding the possibility of biosimilars entering the market before the patent expires.
Not addressed in the provided prescribing information excerpts.
Generic versions of Xarelto are expected to become available within a few months after the patent expires.
Not addressed in the provided prescribing information excerpts.
Generic Xarelto availability after patent expiry depends on regulatory approval.
Not addressed in the provided prescribing information excerpts.
Generic Xarelto availability after patent expiry depends on the ability of manufacturers to scale up production.
Not addressed in the provided prescribing information excerpts.
It is expected that generic Xarelto will become available to patients in early 2029 or even later, pending FDA approval of the generic manufacturer.
Not addressed in the provided prescribing information excerpts.
Contradictions
Important Omissions
Details on dosage and administration, contraindications, boxed warnings, warnings/precautions, drug interactions, and adverse reactions are not evaluated because the provided label excerpts only cover indications.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported claims present are about approved indications; the remaining claims relate to patent/generic/biosimilar timing and are not prescribing-information safety assertions based on the provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several non-label claims (patent status/timing, generic launch plans, biosimilar timelines) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to label-supported sections (e.g., indications in 1.1–1.3) or provide the relevant label text sections for patent/generic/biosimilar and regulatory-timing claims before asserting them.